B O Oyajobi

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. ncbi request reprint Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy
    B O Oyajobi
    Department of Medicine, University of Texas Health Science Center at San Antonio, 78229, USA
    Cancer Res 61:2572-8. 2001
  2. ncbi request reprint Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease
    Babatunde O Oyajobi
    Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Br J Haematol 139:434-8. 2007
  3. ncbi request reprint Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma
    Babatunde O Oyajobi
    Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 3900, USA
    Cancer 97:813-7. 2003
  4. ncbi request reprint Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
    Babatunde O Oyajobi
    Department of Cellular and Structural Biology MSC 7762, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Blood 102:311-9. 2003
  5. pmc Multiple myeloma/hypercalcemia
    Babatunde O Oyajobi
    University of Texas Health Science Center at San Antonio, Department of Cellular and Structural Biology MSC 7762, San Antonio, Texas 78229 3900, USA
    Arthritis Res Ther 9:S4. 2007
  6. ncbi request reprint Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging
    Babatunde O Oyajobi
    Department of Cellular and Structural Biology MSC 7762, University of Texas Health Science Center at San Antonio, Texas 78229 3900, USA
    Mol Cancer Ther 6:1701-8. 2007
  7. ncbi request reprint E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation
    Ming Zhao
    Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    J Biol Chem 278:27939-44. 2003
  8. doi request reprint Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma
    K R Kelly
    Department of Medicine, The Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX 78229, USA
    Oncogene 31:3023-38. 2012
  9. pmc The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling
    Ming Zhao
    Department of Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Mol Cell Biol 26:6197-208. 2006
  10. ncbi request reprint Advances in the management of myeloma bone disease
    Claire M Shipman
    Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Expert Opin Pharmacother 6:2781-91. 2005

Research Grants

  1. NF-kappaB in myeloma cell growth and survival in vivo
    Babatunde Oyajobi; Fiscal Year: 2007

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy
    B O Oyajobi
    Department of Medicine, University of Texas Health Science Center at San Antonio, 78229, USA
    Cancer Res 61:2572-8. 2001
    ..Fc in vivo as well as highlight the potential utility of disrupting RANK signaling as a novel therapeutic approach in humoral hypercalcemia of malignancy and possibly multiple myeloma and skeletal metastases associated with osteolysis...
  2. ncbi request reprint Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease
    Babatunde O Oyajobi
    Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Br J Haematol 139:434-8. 2007
    ..Clinical trials in patients with myeloma bone disease are needed to validate these results...
  3. ncbi request reprint Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma
    Babatunde O Oyajobi
    Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 3900, USA
    Cancer 97:813-7. 2003
    ..We provide "proof of principle" in preclinical myeloma models that these are indeed valid molecular targets in development of novel therapeutics...
  4. ncbi request reprint Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
    Babatunde O Oyajobi
    Department of Cellular and Structural Biology MSC 7762, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Blood 102:311-9. 2003
    ..Because, in the 5TGM1 model, blockade of osteoclastic resorption in other situations does not decrease tumor burden, we conclude that MIP-1alpha exerts a dual effect in myeloma, on osteoclasts, and tumor cells...
  5. pmc Multiple myeloma/hypercalcemia
    Babatunde O Oyajobi
    University of Texas Health Science Center at San Antonio, Department of Cellular and Structural Biology MSC 7762, San Antonio, Texas 78229 3900, USA
    Arthritis Res Ther 9:S4. 2007
    ....
  6. ncbi request reprint Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging
    Babatunde O Oyajobi
    Department of Cellular and Structural Biology MSC 7762, University of Texas Health Science Center at San Antonio, Texas 78229 3900, USA
    Mol Cancer Ther 6:1701-8. 2007
    ..Whole-body GFP imaging is practical, convenient, inexpensive, and rapid, and these advantages should enable a high throughput when evaluating in vivo efficacy of new potential antimyeloma therapeutics and assessing response to treatment...
  7. ncbi request reprint E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation
    Ming Zhao
    Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    J Biol Chem 278:27939-44. 2003
    ..Smurf1 therefore appears to be an important regulatory factor in osteoblast differentiation and a potential molecular target for identification of bone anabolic agents...
  8. doi request reprint Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma
    K R Kelly
    Department of Medicine, The Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center, San Antonio, TX 78229, USA
    Oncogene 31:3023-38. 2012
    ..Furthermore, reovirus infection can be used as a promising approach to augment the anti-myeloma activity of bortezomib by promoting additional stress to the endoplasmic reticulum of MM cells...
  9. pmc The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling
    Ming Zhao
    Department of Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Mol Cell Biol 26:6197-208. 2006
    ..Taken together, these results indicate that Gli2 mediates hedgehog signaling in osteoblasts and is a powerful activator of BMP-2 gene expression, which is required in turn for normal osteoblast differentiation...
  10. ncbi request reprint Advances in the management of myeloma bone disease
    Claire M Shipman
    Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Expert Opin Pharmacother 6:2781-91. 2005
    ..However, as our understanding of the molecular mechanisms involved in the development of myeloma bone disease increases, new molecular targets have been identified for the treatment of this devastating bone disease...
  11. ncbi request reprint Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
    S L Dallas
    Department of Medicine Division of Endocrinology and Metabolism, and the Department of Pathology, University of Texas Health Science Center at San Antonio, TX, USA
    Blood 93:1697-706. 1999
    ..These results support clinical findings that bisphosphonates may be useful for the treatment of myeloma-associated bone destruction, but suggest that other therapies are also required to reduce tumor growth...
  12. pmc Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo
    Ming Zhao
    Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    J Biol Chem 279:12854-9. 2004
    ..In these transgenic mice, bone formation was significantly reduced during postnatal life. Our results demonstrate for the first time that Smurf1 plays a specific role in osteoblast differentiation and bone formation in vivo...
  13. ncbi request reprint The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells
    Julie A Sterling
    Department of Cellular and Structural Biology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Cancer Res 66:7548-53. 2006
    ..Together, these data suggest that PTHrP expression and osteolysis in vivo in human breast cancer cells is driven at least in part by Gli2...
  14. ncbi request reprint Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions
    Suresh Mohla
    Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20892, USA
    Cancer 97:719-25. 2003
    ....
  15. pmc Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
    Claire M Edwards
    Department of Cancer Biology, Vanderbilt Center for Bone Biology, Vanderbilt University, Nashville, TN 37232, USA
    Blood 111:2833-42. 2008
    ....

Research Grants2

  1. NF-kappaB in myeloma cell growth and survival in vivo
    Babatunde Oyajobi; Fiscal Year: 2007
    ..The research outlined will provide the basis for generation of novel therapeutic approaches to treat MM. ..